Therakind, a private European pharmaceutical company, is focused on creating and developing safe, effective, authorised paediatric and speciality niche medicines. Our primary objective is to increase the availability of authorised paediatric and niche medicines and to ensure that the medication used today is both safe and effective. Therakind's team has extensive experience in the paediatric pharmaceutical sector, we have the expertise to design clinical programmes and regulatory strategy to advance medicines from concept through to regulatory approval. Therakind was pivotal in the process of bringing Buccolam®, a treatment for prolonged acute convulsive seizures, to the EU market. This product has been sold to Viropharma Inc (now Shire Pharmaceuticals) and is marketed across Europe. Therakind is a private European pharmaceutical company established in 2006.